Derek Lowe: “I can’t see how the current review process won’t get broken if Pfizer’s motion is granted. The whole issue is whether the journal’s editors can claim privilege – if so, they don’t have to release, and if not, they most certainly do. This can’t help but set a precedent, one way or another. If there’s no privilege involved in the editorial process, a lot of qualified and competent reviewers will start turning down any manuscript that might someday be involved in legal action.”
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
